Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
This page provides a historical news archive for Accolade, Inc. (formerly Nasdaq: ACCD), a Personalized Healthcare company that combined virtual primary care and mental health, expert medical opinion, and care navigation for employers, health plans, and consumers. The news flow around Accolade documents its evolution as a public company and its eventual merger with Transcarent.
Readers can find company-issued announcements describing Accolade’s financial results, investor conference presentations, and guidance updates during its time as a listed company. These items include earnings releases, notices about upcoming quarterly results, and participation in healthcare and investor conferences, all framed around its Personalized Healthcare platform and focus on predictive engagement, proactive care, and addressing barriers to access and continuity of care.
The archive also includes press releases detailing strategic developments, such as the expansion of PlushCare, Accolade’s virtual health business unit, to accept Medicare Part B for direct-to-consumer virtual care. These releases describe efforts to broaden access to primary care, clinical weight management services, and mental health support for Medicare beneficiaries across all 50 states.
A significant portion of the news coverage centers on the acquisition of Accolade by Transcarent. Initial announcements describe a definitive agreement for Transcarent to acquire Accolade for cash consideration per share, followed by stockholder approval of the merger and, later, confirmation that the transaction was completed. These items explain that, after the merger, Accolade became part of a privately held company and its common stock would no longer be listed on Nasdaq or any public market.
Investors and researchers can use this news page to trace how Accolade positioned its Personalized Healthcare offerings, how it communicated with the market, and how the combination with Transcarent was described by both organizations over time.
Priority Health has formed a strategic partnership with Accolade to enhance healthcare experiences for Michigan employers and their members. This collaboration aims to leverage virtual care and personalized navigation to drive employee engagement and reduce healthcare costs. Through their integrated approach, the two organizations will deliver unique health offerings that prioritize quality and value. This partnership aligns with Priority Health's growth objectives as the state's fastest-growing health plan, while Accolade focuses on empowering individuals to make informed healthcare decisions.
Accolade (Nasdaq: ACCD) has released findings from a report showing how its Personalized Healthcare services enhance employee retention, recruitment, and satisfaction. The research indicates that 93% of Accolade members find their healthcare experience easier, while 92% report improved benefits. The study highlights the importance of mental health and virtual healthcare in the competitive talent market, with 61% of employers looking to expand these services. Key findings show that Accolade members value their health benefits more than non-members, indicating a positive perception of their employer's offerings.
Accolade, Inc. (NASDAQ: ACCD) will participate in the 2022 SVB Leerink Global Healthcare Conference, featuring a fireside chat presentation scheduled for February 18, 2022, at 2:20 p.m. E.T. This event highlights Accolade's commitment to transforming healthcare through personalized, data-driven solutions that enhance member experience.
Accolade serves over 600 employers and millions of members, providing virtual primary care, mental health support, and expert medical opinions, achieving consumer satisfaction ratings above 90%. For more details, visit accolade.com.
Accolade, Inc. (NASDAQ: ACCD) will participate in the 24th Annual Needham Growth Conference, presenting on January 14, 2022, at 12:30 p.m. E.T. The event will be accessible via webcast at ir.accolade.com. Accolade provides personalized healthcare solutions, including virtual primary care and mental health support, serving over 600 employers and millions of members. The company emphasizes a data-driven and value-based approach to healthcare, achieving consumer satisfaction ratings above 90%. For further details, visit accolade.com.
Accolade, Inc. (NASDAQ: ACCD) reported fiscal Q3 2022 revenue of $83.5 million, marking a significant 117% increase from Q3 2021. The company aims for 25% revenue growth in fiscal 2023 while reducing Adjusted EBITDA loss. CEO Rajeev Singh highlighted the transformation into a personalized healthcare provider, growing from 100 customers and 2 million members to over 600 customers and 10 million members in just one year. Accolade successfully launched the Accolade Care and Accolade One services on January 1, 2022, further enhancing their healthcare offerings.
Accolade, Inc. (NASDAQ: ACCD) will release its fiscal Q3 2022 financial results on January 10, 2022, after market close. A conference call will follow at 4:30 p.m. E.T. to discuss these results. The call can be accessed by dialing 1-833-519-1281 for U.S. participants or 1-914-800-3853 for international participants, using conference ID # 6077524. A live audio webcast will also be available on the company's investor relations website. The replay of the call will be accessible for approximately 90 days after the event.
Accolade, Inc. (NASDAQ: ACCD) will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference, accessible for registered attendees until December 2, 2021. The company supports over 400 employers and millions of members, focusing on personalized, data-driven healthcare experiences. Accolade combines virtual primary care, mental health support, and expert medical opinions through advanced technology, achieving consumer satisfaction ratings above 90%. For more details, visit accolade.com.
Accolade (Nasdaq: ACCD) has announced an expansion of its executive leadership team, welcoming Carolina Lobo as chief marketing officer and Eve Stacey as chief customer officer. This strategic move aims to enhance the company’s Personalized Healthcare offerings, fostering better healthcare experiences for over 400 enterprise customers and nine million members. Lobo will lead brand strategy and engagement, while Stacey will focus on customer success operations. Both leaders bring extensive experience from notable companies, positioning Accolade to strengthen its mission in delivering exceptional healthcare solutions.
Accolade, Inc. (NASDAQ: ACCD) will participate in the Credit Suisse 30th Annual Healthcare Conference with a fireside chat on November 11, 2021, at 12:10 p.m. E.T. The session will be accessible through a webcast on their investor relations website, ir.accolade.com. Accolade is a healthcare provider that offers personalized care solutions to over 400 employers and millions of members, focusing on a value-based approach to improve healthcare outcomes and maintain high consumer satisfaction ratings above 90%.
Summary not available.